Japan’s Takeda Pharmaceutical will develop next-gen oncology therapies as part of a new collaboration agreement with Texan biotech company Molecular Templates.
The collaboration will apply Molecular Templates’ engineered toxin bodies technology platform to potential therapeutic targets provided by Takeda through a joint scientific committee of both companies.
“Over the past year, Takeda has expanded its collaborations in the oncology space with the aim of accessing highly-innovative platforms to target specific tumour antigens using novel payloads and modality approaches,” said Christopher Arendt, Ph.D., Head, Oncology DDU & Immunology Unit, Takeda.
He added: “In fact, we had already been working with the Molecular Templates team on a program that we have the option to in-license.
“[The collaboration] allows us to extend this partnership and leverage their potentially groundbreaking approach to address additional tumour types, including solid tumours.”
Takeda will make an equity investment and Molecular Templates is eligible to receive upfront payments, development and commercial milestone payments.
“This collaboration is an exciting opportunity to develop a new class of oncology therapeutics by applying our modified Shiga-like toxin fusion proteins to Takeda’s world-class oncology target portfolio,” said Eric Poma, Ph.D., Molecular Templates’ Chief Executive and Scientific Officer.